Clearmind Medicine Continues Successful Treatment of Participants in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Clearmind Medicine has announced the successful continuation of treatment in its FDA-approved Phase I/IIa clinical trial for Alcohol Use Disorder. Patients at Yale University, Johns Hopkins University, and Tel Aviv Sourasky Medical Center have progressed successfully through the treatment protocol, demonstrating safety and tolerability with no serious adverse events reported. This positive progress follows the Company's recent announcement regarding the advancement of participant enrollment for the third cohort.